Literature DB >> 28509189

The importance of medical interview with CKD patient in diagnoses of a family with Fabry disease.

Yuichi Sakamaki1,2, Hiroki Maruyama3, Noriyuki Homma4, Gen Nakamura4, Eiichi Ito4, Kunihiko Makino4, Kazuhiro Yoshita5, Yumi Ito5, Yutaka Osawa5, Naofumi Imai5, Mitsuhiro Ueno6, Shigeru Miyazaki7, Ichiei Narita5.   

Abstract

A 47-year-old Japanese man was admitted to our hospital for evaluation of proteinuria, which was detected when he was 37 years of age. His creatinine clearance levels had fallen to 76.3 mL/min/1.73 m2. A kidney biopsy was conducted, and the patient's low plasma α-galactosidase A levels suggested Fabry disease. After genetic counseling, GLA analysis revealed a novel mutation p.L387P. Interview with the patient revealed that both his younger brother and mother suffered from cardiomyopathy and were undergoing cardiological treatment. They also were positive for proteinuria. About 30 years ago, the patient's cousin (aged 25) was diagnosed with Fabry disease. He underwent hemodialysis for 9 years until his death at 42. At that time, the patient and his brother had not been investigated for Fabry disease so their cousin could not act as a proband for the brothers. Eventually, the patient, his mother, and his brother were put on enzyme replacement therapy with agalsidase beta. As this series of cases shows, medical interviews to collate both medical and family history were essential for the discovery of Fabry disease in these patients. In addition, being a treatable genetic disorder, Fabry disease should be listed in the standard differential diagnoses of systemic and familial diseases, including unknown cause of nephropathy or cardiomyopathy, for early detection of the disorder.

Entities:  

Keywords:  Enzyme replacement therapy; Fabry disease; Familial study; Genetic counseling

Year:  2014        PMID: 28509189      PMCID: PMC5411562          DOI: 10.1007/s13730-014-0108-3

Source DB:  PubMed          Journal:  CEN Case Rep        ISSN: 2192-4449


  13 in total

1.  Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene.

Authors:  L Ferri; C Guido; G la Marca; S Malvagia; C Cavicchi; A Fiumara; R Barone; R Parini; D Antuzzi; C Feliciani; A Zampetti; R Manna; S Giglio; C M Della Valle; X Wu; K J Valenzano; R Benjamin; M A Donati; R Guerrini; M Genuardi; A Morrone
Journal:  Clin Genet       Date:  2011-05-25       Impact factor: 4.438

2.  A novel GLA mutation in a Fabry family with glucose-6-phosphate dehydrogenase deficiency.

Authors:  Antonio Pisani; Bianca Visciano; Roberta Russo; Giusi R Mozzillo; Caterina Porto; Ilaria De Maggio; Roberta Russo; Gianfranco Pontarelli; Guglielmo R D Villani; Bruno Cianciaruso; Paola Di Natale
Journal:  J Nephrol       Date:  2012 Jul-Aug       Impact factor: 3.902

3.  Significance of screening for Fabry disease among male dialysis patients.

Authors:  Mayuri Ichinose; Masaaki Nakayama; Toya Ohashi; Yasunori Utsunomiya; Masahisa Kobayashi; Yoshikatsu Eto
Journal:  Clin Exp Nephrol       Date:  2005-09       Impact factor: 2.801

4.  Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.

Authors:  M Tanaka; T Ohashi; M Kobayashi; Y Eto; N Miyamura; K Nishida; E Araki; K Itoh; K Matsushita; M Hara; K Kuwahara; T Nakano; N Yasumoto; H Nonoguchi; K Tomita
Journal:  Clin Nephrol       Date:  2005-10       Impact factor: 0.975

5.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

6.  Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

Authors:  Shoichiro Nakao; Chihaya Kodama; Toshihiro Takenaka; Akihiro Tanaka; Yuichiro Yasumoto; Aichi Yoshida; Tamotsu Kanzaki; Annette L D Enriquez; Christine M Eng; Hiromitsu Tanaka; Chuwa Tei; Robert J Desnick
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

Review 7.  Fabry's disease.

Authors:  Yuri A Zarate; Robert J Hopkin
Journal:  Lancet       Date:  2008-10-18       Impact factor: 79.321

8.  Screening of male dialysis patients for fabry disease by plasma globotriaosylsphingosine.

Authors:  Hiroki Maruyama; Takuma Takata; Yutaka Tsubata; Ryushi Tazawa; Kiyoe Goto; Jun Tohyama; Ichiei Narita; Hidekatsu Yoshioka; Satoshi Ishii
Journal:  Clin J Am Soc Nephrol       Date:  2013-01-10       Impact factor: 8.237

9.  Prevalence of lysosomal storage disorders.

Authors:  P J Meikle; J J Hopwood; A E Clague; W F Carey
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

Review 10.  Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.

Authors:  Christine M Eng; Dominique P Germain; Maryam Banikazemi; David G Warnock; Christoph Wanner; Robert J Hopkin; Jan Bultas; Philip Lee; Katherine Sims; Scott E Brodie; Gregory M Pastores; Joerg M Strotmann; William R Wilcox
Journal:  Genet Med       Date:  2006-09       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.